| Lucia Catherine Benzoni, DO | |
|
622 Bantam Rd, Bantam, CT 06750-1600 | |
| (860) 567-1263 | |
| Not Available |
| Full Name | Lucia Catherine Benzoni |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 622 Bantam Rd, Bantam, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285660308 | NPI | - | NPPES |
| 001005190 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 000519 (Connecticut) | Secondary |
| 207R00000X | Internal Medicine | 000519 (Connecticut) | Secondary |
| 208000000X | Pediatrics | 000519 (Connecticut) | Primary |
| Entity Name | Bristol Hospital Multi-specialty Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649265679 PECOS PAC ID: 9032014758 Enrollment ID: O20031204000960 |
News Archive
A new study, led by scientists at The Scripps Research Institute, reveals a surprising twist in immune biology.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.
Elevated low-density lipoprotein (LDL) or bad cholesterol level is an established risk factor for developing cardiovascular disease (CVD), including heart disease, hypertension, and stroke. Contrary to current claims that coconut oil can benefit cardiovascular health, a new study combining 16 published research shows that consumption of coconut oil is linked to higher levels of LDL and total cholesterol levels.
A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.
› Verified 9 days ago
| Entity Name | The Charlotte Hungerford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629075734 PECOS PAC ID: 4486557501 Enrollment ID: O20040128000183 |
News Archive
A new study, led by scientists at The Scripps Research Institute, reveals a surprising twist in immune biology.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.
Elevated low-density lipoprotein (LDL) or bad cholesterol level is an established risk factor for developing cardiovascular disease (CVD), including heart disease, hypertension, and stroke. Contrary to current claims that coconut oil can benefit cardiovascular health, a new study combining 16 published research shows that consumption of coconut oil is linked to higher levels of LDL and total cholesterol levels.
A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.
› Verified 9 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
A new study, led by scientists at The Scripps Research Institute, reveals a surprising twist in immune biology.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.
Elevated low-density lipoprotein (LDL) or bad cholesterol level is an established risk factor for developing cardiovascular disease (CVD), including heart disease, hypertension, and stroke. Contrary to current claims that coconut oil can benefit cardiovascular health, a new study combining 16 published research shows that consumption of coconut oil is linked to higher levels of LDL and total cholesterol levels.
A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lucia Catherine Benzoni, DO Po Box 427, Litchfield, CT 06759-0427 Ph: (860) 567-1263 | Lucia Catherine Benzoni, DO 622 Bantam Rd, Bantam, CT 06750-1600 Ph: (860) 567-1263 |
News Archive
A new study, led by scientists at The Scripps Research Institute, reveals a surprising twist in immune biology.
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.
Elevated low-density lipoprotein (LDL) or bad cholesterol level is an established risk factor for developing cardiovascular disease (CVD), including heart disease, hypertension, and stroke. Contrary to current claims that coconut oil can benefit cardiovascular health, a new study combining 16 published research shows that consumption of coconut oil is linked to higher levels of LDL and total cholesterol levels.
A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.
› Verified 9 days ago